Skip to main content

Table 4 Crude and adjusted hazard ratios for the association between a variable and the risk of NTM infection within the 1st year after the diagnosis

From: The risk of nontuberculous mycobacterial infection in patients with Sjögren’s syndrome: a nationwide, population-based cohort study

  Univariate analysis Model A Model B
  HR (95%CI) HR (95%CI) HR (95%CI)
Group
 Non- SS Reference Reference Reference Reference Reference Reference
 SS 16.06 (3.24–79.60) 5.22 (0.71–38.64)   
  SS treated without immunosuppressants 6.28 (0.65–60.42)    4.04 (0.39–41.85)
  SS treated with immunosuppressants 72.39 (12.09–433.31)    33.33 (4.37–254.23)
Age
  < 50 years Reference Reference Reference Reference Reference Reference
  ≥ 50 years 2.66 (0.31–22.76) 1.60 (0.17–15.09) 1.61 (0.17–15.25)
Gender
 Female Reference Reference Reference Reference Reference Reference
 Male 3.81 (0.70–20.79) 2.92 (0.53–16.19) 2.85 (0.51–15.80)
CCI group
 0 Reference Reference Reference Reference Reference Reference
  ≥ 1 6.89 (1.26–37.61) 4.05 (0.67–24.28) 4.16 (0.69–24.98)
Medications
 Immunosuppressants 39.16 (7.17–213.81) 6.21 (0.75–51.40)   
 Steroid 6.94 (1.27–37.90) 2.55 (0.37–17.46) 2.65 (0.38–18.24)
  1. Immunosuppressants: methotrexate, cyclophosphamide, or azathioprine. Abbreviations: SS Sjögren’s Syndrome, CCI Charlson comorbidity index